Bayer Builds China Diabetes Portfolio with SciLin Launch

Bayer Schering Pharma has launched SciLin, its recombinant insulin product, in China. In June 2009, the company paid $43.5 million to Polish biotech Bioton for China rights to the drug over the next 15 years. At the time of the agreement, Bayer forecast that SciLin would generate between $1.5 billion and $2 billion of revenue in China during the life of the agreement. More details.... Stock Symbol: (XETRA: BAY)